Observations of HIV-1 genotypic drug resistance in a trial of four reverse transcriptase inhibitors (Quattro Trial)

Antiviral Therapy

Volumn 7, Issue 1, 2002, Pages 11-20

  Kaye, S ^a   Dunn, D T ^a   Babiker, A G ^a   Darbyshire, J H ^a   Hooker, M H ^a   Nesarantnam, S ^a   Newberry, A ^a   Weber, J ^a   Breckenridge, A ^a   Back, D ^a   Blatchford, N ^a   Gazzard, B ^a   Gartland, M ^a   Hooker, M ^a   Jeffries, D ^a   Johnson, M ^a   Plummer, K ^a   Wills, B ^a   Kitchen, V ^a   Loveday, C ^a   Tedder, R ^a   Weller, I V D ^a   Withnall, R ^a   more..

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

LAMIVUDINE; LOVIRIDE; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZALCITABINE; ZIDOVUDINE;

ARTICLE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MUTATION; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; VIRUS LOAD; VIRUS REPLICATION; VIRUS RESISTANCE;

EID: 0036523769     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Chow YK, Hirsch MS, Merrill DP, Bechtel LJ, Eron JJ, Kaplan JC & D'Aquila RT. Use of evolutionary limitations of HIV-1 multidrug resistance to optimize therapy. Nature 1993; 361:650-654.
2. Chow YK, Hirsch MS, Kaplan JC & D'Aquila RT. HIV-1 error revealed. Nature 1993; 364:679.
3. Larder B, Richman D & Vella S. HIV resistance and implications for therapy. 1998. Atlanta: Medicom Inc.
4. Richman DD, Havlir D, Corbeil J, Looney D, Ignacio C, Spector SA, Sullivan J, Cheeseman S, Barringer K, Pauletti D, Cheng-Kon S, Myers M & Griffin J. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. Journal of Virology 1994; 68:1660-1666.
5. Quattro Steering Committee. A randomized trial comparing regimens of four reverse transcriptase inhibitors given together or cyclically in HIV-1 infection - the Quattro Trial. AIDS 1999; 13:2209-2217.
6. Kaye S. Viral genotyping by a quantitative point mutation assay: application to HIV-1 drug resistance. In PCR Applications 1999. Edited by MA Iniiis, DH Gelfand & JJ Sninsky. San Diego: Academic Press.
7. Stuyver L, Wyseur A, Rombout A, Verhofstede C, Rimland D, Schinazi RF & Rossau R. Line probe assay for rapid detection of drug selected mutations in the human immunodeficiency virus reverse transcriptase gene. Antimicrobial Agents and Chemotherapy 1997; 41:284-291.
8. Clarke JR, Kaye S, Babiker AG, Hooker MH, Tedder R & Weber JN. Comparison of a point mutation assay with a line probe assay for the detection of the major mutations in the HIV-1 reverse transcriptase gene associated with reduced susceptibility to nucleoside analogues. Journal of Virological Methods 2000; 88:117-124.
9. Boom R, Sol CJA, Salimans MMM, Jansen CL, Wertheim van Dillen PME & van der Noordaa J. Rapid and simple method for purification of nucleic acids. Journal of Clinical Microbiology 1990; 28:495-503.
10. Boucher CAB, O'Sullivan E, Mulder JW, Ramaurtarsing C, Kellam P, Darby G, Lange JMA, Goudsmit J & Larder BA (1992). Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects. Journal of Infectious Diseases 1992; 165:105-110.
11. Schinazi RF, Larder BA & Mellors JW. Mutations in retroviral genes associated with drug resistance: 2000-2001 update. International Antiviral News 2000; 8:65-91.
12. Korber B, Kuiken C, Foley B, Hahn B, McCutchen F, Mellors J & Sodroski J. Human Retroviruses and AIDS. 1998. Los Almos: Los Alamos National Laboratory.
13. Katlama C, Ingrand D, Loveday C, Clumeck N, Mallolas J, Staszewski S, Johnson M, Hill AM, Pearce G & McDade H. Safety and efficacy of lamivudine-zidovudine combination therapy in anti-retroviral-naïve patients: a randomised controlled comparison with zidovudine monotherapy. Journal of the American Medical Association 1996; 276:118-125.
14. Schuurman R, Nijhuis M, Van Leeuwen R, Schipper P, de Jong D, Collis P, Danner SA, Mulder J, Loveday C, Christopherson C, Kwok S, Sninsky J & Boucher CAB. Rapid changes in human immunodeficiency virus type-1 RNA load and appearance of drug resistant virus populations in persons treated with lamivudine (3TC). Journal of Infectious Diseases 1995; 171:1411-1419.
15. Kuritzkes DR, Quinn JB, Benoit SL, Shugarts DL, Griffin A, Bakhtiani M, Poticha D, Eron JJ, Fallon MA & Rubin M. Drug resistant and virologic response in NUCA 3001, a randomised trial of lamivudine (3TC) versuszidovudine (ZDV) versus zidovudine plus lamivudine in previously untreated patients. AIDS 1996; 10:975-981.
16. Brun-Vezinet F, Boucher C, Loveday C, Descamps D, Fauveau V, Izopet J, Jeffries D, Kaye S, Krzyanowski C, Nunn A, Schuurman R, Seigneurin J-M, Tamalet C, Tedder RS, Weber J & Weverling G-J. HIV-1 virus load, phenotype and resistance in a subset of drug-naive participants from the Delta Trial. Lancet 1996; 350:983-990.
17. Gatell J, Lange J & Gartland M. AVANTI 1: randomized double-blind trial to evaluate the safety and efficacy of zidovudine plus lamivudine versus zidovudine plus lamivudine plus loviride in HIV-infected antiretroviral-naïve patients. Antiviral Therapy 1999; 4:79-86.
18. Loveday C, Kaye S, Tenant-Flowers M, Semple M, Ayliffe U, Weller IVD & Tedder RS. HIV-1 RNA serum-load and resistant viral genotypes during early zidovudine therapy. Lancet 1995; 345:820-824.
19. McLean AR, Emery VC, Webster A & Griffiths PD. Population dynamics of HIV within an individual after treatment with zidovudine. AIDS 1991; 5:485-489.
20. De Jong MD, Veenstra J, Stilianakis NI, Schuurman R, Lange JM, de Boer RJ & Boucher CAB. Host-parasite dynamics and outgrowth of virus containing a single K70R amino acid change in reverse transcriptase are responsible for the loss of human immunodeficiency virus type 1 RNA load suppression by zidovudine. Proceedings of the Nationat Academy of Sciences USA 1996; 93:5501-5506.
21. Fitzgibbon JE, Howell RM, Haberzettl CA, Sperber SJ, Gocke DJ & Dubin DT. Human immunodeficiency virus type 1 pol gene mutations which cause decreased susceptibility to 2′,3′-dideoycytidine. Antimicrobial Agents and Chemotherapy 1992; 36:153-157.
22. Barry MG, Khoo SH, Veal GJ, Hoggard PG, Gibbons SE, Wilkins EG, Williams O, Breckenridge AM & Back DT. The effects of zidovudine dose on the formation of intracellular phosphorylated metabolites. AIDS 1996; 10:1361-1367.
23. Kewn S, Veal GJ, Hoggard PG, Barry MG & Back DJ. Lamivudine (3TC) phosphorylation and drug interactions in vitro. Biochemical Pharmacology 1997; 54:589-595.
24. Back NKT, Nijhuis M, Keulen W, Boucher CAB, Oude Essink BB, van Kuilenburg ABP, van Gennip AH & Berkhout B. Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme. European Molecular Biology Organization Journal 1996; 15:4040-4049.
25. Arts EJ, Quinones-Mateu ME, Albright JL, Marois JP, Hough C, Gu Z & Wainberg MA. 3′-azido-3′-deoxythymidine (AZT) mediates cross-resistance to nucleoside analogs in the case of AZT-resistant human immunodeficiency virus type 1 variants. Journal of Virology 1998; 72:4858-4865.